口服二甲双胍使用与糖尿病患者年龄相关性黄斑变性发病风险的关联:系统综述与Meta分析
该系统综述与Meta分析检索Ovid MEDLINE/Embase、Cochrane Library和Web of Science数据库至2022年8月3日,纳入9项观察性研究共1,446,284名参与者,发现二甲双胍使用与年龄相关性黄斑变性(AMD)风险降低相关(合并OR=0.81,95%CI=0.70-0.93)。亚组分析显示二甲双胍使用与干性或湿性AMD无显著关联,黑人和西班牙裔人群AMD风险显著降低。作者认为需要前瞻性临床试验来证实这一关联。
要点
- 二甲双胍使用与AMD风险降低相关(合并OR=0.81,95%CI=0.70-0.93)。
- 亚组分析显示二甲双胍使用与干性或湿性AMD无显著关联。
- 黑人和西班牙裔人群使用二甲双胍后AMD风险显著降低。
核心结论
- 该系统综述与Meta分析发现,使用二甲双胍的糖尿病患者发生AMD的风险较低。
- 作者认为需要未来的前瞻性临床试验来证实这一关联。
研究设计与样本
- 系统综述与Meta分析,检索Ovid MEDLINE/Embase、Cochrane Library和Web of Science数据库,检索时间从建库至2022年8月3日。
- 纳入报告二甲双胍使用与AMD风险关联的研究,共纳入9项观察性研究,合计1,446,284名参与者。
- 提取AMD的调整比值比(OR),采用随机效应模型进行Meta分析。
- 根据AMD亚型、种族、研究设计、性别和AMD诊断确认方式进行亚组分析。
主要发现
- 二甲双胍使用与AMD风险显著降低相关(合并OR=0.81,95%CI=0.70-0.93)。
- 亚组分析显示,二甲双胍使用与干性AMD或湿性AMD均无显著关联。
- 黑人人群使用二甲双胍后AMD风险显著降低(合并OR=0.61,95%CI=0.58-0.64)。
- 西班牙裔人群使用二甲双胍后AMD风险显著降低(合并OR=0.85,95%CI=0.81-0.89)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需要未来的前瞻性临床试验来证实这一关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Metformin is a biguanide derivative that is commonly used for the treatment of diabetes mellitus (DM). It demonstrates antioxidative, anti-inflammatory, and antiangiogenic activity within the ocular tissue and thus may be implicated in the treatment of age-related macular degeneration (AMD). However, epidemiological studies have shown conflicting results. METHODS: The Ovid MEDLINE/Embase, Cochrane Library, and Web of Science databases were systematically searched from inception through August 3, 2022. Studies reporting the association between metformin use and odds of AMD were enrolled. Adjusted odds ratios (ORs) of AMD were extracted and pooled with random-effects model meta-analysis. Subgroup analyses based on AMD subtypes, ethnicity, study design, sex, and confirmation of AMD diagnosis were conducted. RESULTS: A total of 9 observational studies with 1,446,284 participants were included in the analysis. The meta-analysis showed that metformin use was associated with a significant reduction in the odds of AMD (pooled ORs = 0.81, 95% confidence interval [CI] = 0.70-0.93). Subgroup analyses revealed that metformin use was not significantly associated with dry or wet AMD. Black (pooled ORs = 0.61, 95% CI = 0.58-0.64) and Hispanic populations (pooled ORs = 0.85, 95% CI = 0.81-0.89) demonstrated significantly lower odds of AMD. CONCLUSIONS: This systematic review and meta-analysis found that patients with DM with metformin usage were at lower odds of developing AMD. Future prospective clinical trials are needed to confirm this association.
引用
- Liang KH, Chen CH, Tsai HR, et al. Association Between Oral Metformin Use and the Development of Age-Related Macular Degeneration in Diabetic Patients: A Systematic Review and Meta-Analysis. Invest Ophthalmol Vis Sci. 2022. PMID: 36484633. doi:10.1167/iovs.63.13.10
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。